Aneta Piwowarczyk-Nowak1, Artur Pałasz2, Aleksandra Suszka-Świtek3, Alessandra Della Vecchia4, Aniela Grajoszek5, Marek Krzystanek6, John J Worthington7. 1. Department of Anatomy, Faculty of Medical Sciences in Katowice, Medical University of Silesia, ul. Medyków 18, 40-752, Katowice, Poland. 2. Department of Histology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, ul. Medyków 18, 40-752, Katowice, Poland. apalasz@sum.edu.pl. 3. Department of Histology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, ul. Medyków 18, 40-752, Katowice, Poland. 4. Section of Psychiatry, Department of Clinical and Experimental Medicine, University of Pisa, 67, Via Roma, 56100, Pisa, Italy. 5. Department for Experimental Medicine, Medical University of Silesia, ul. Medyków 4, 40-752, Katowice, Poland. 6. Department of Psychiatry and Psychotherapy, Faculty of Medical Sciences in Katowice, Clinic of Psychiatric Rehabilitation, Medical University of Silesia, ul. Ziolowa 45/47, 40-635, Katowice, Poland. 7. Division of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster, LA1 4YQ, UK.
Abstract
BACKGROUND: Neuropeptide S (NPS) is a multifunctional regulatory factor that exhibits a potent anxiolytic activity in animal models. However, there are no reports dealing with the potential molecular relationships between the anxiolytic activity of selective serotonin reuptake inhibitors (SSRIs) and NPS signaling, especially in the context of novel stress-related neuropeptides action. The present work therefore focused on gene expression of novel stress neuropeptides in the rat brain after acute treatment with escitalopram and in combination with neuropeptide S receptor (NPSR) blockade. METHODS: Studies were carried out on adult, male Sprague-Dawley rats that were divided into five groups: animals injected with saline (control) and experimental rats treated with escitalopram (at single dose 10 mg/kg daily), escitalopram and SHA-68, a selective NPSR antagonist (at a single dose of 40 mg/kg), SHA-68 alone and corresponding vehicle (solvent SHA-68) control. To measure anxiety-like behavior and locomotor activity the open field test was performed. All individuals were killed under anaesthesia and the whole brain was excised. Total mRNA was isolated from homogenized samples of the amygdala, hippocampus, hypothalamus, thalamus, cerebellum, and brainstem. Real-time PCR was used for estimation of related NPS, NPSR, neuromedin U (NMU), NMU receptor 2 (NMUR2) and nesfatin-1 precursor nucleobindin-2 (NUCB2) gene expression. RESULTS: Acute escitalopram administration affects the local expression of the examined neuropeptides mRNA in a varied manner depending on brain location. An increase in NPSR and NUCB2 mRNA expression in the hypothalamus and brainstem was abolished by SHA-68 coadministration, while NMU mRNA expression was upregulated after NPSR blockade in the hippocampus and cerebellum. CONCLUSIONS: The pharmacological effects of escitalopram may be connected with local NPSR-related alterations in NPS/NMU/NMUR2 and nesfatin-1 gene expression at the level of selected rat brain regions. A novel alternative mode of SSRI action can be therefore cautiously proposed.
BACKGROUND: Neuropeptide S (NPS) is a multifunctional regulatory factor that exhibits a potent anxiolytic activity in animal models. However, there are no reports dealing with the potential molecular relationships between the anxiolytic activity of selective serotonin reuptake inhibitors (SSRIs) and NPS signaling, especially in the context of novel stress-related neuropeptides action. The present work therefore focused on gene expression of novel stress neuropeptides in the rat brain after acute treatment with escitalopram and in combination with neuropeptide S receptor (NPSR) blockade. METHODS: Studies were carried out on adult, male Sprague-Dawley rats that were divided into five groups: animals injected with saline (control) and experimental rats treated with escitalopram (at single dose 10 mg/kg daily), escitalopram and SHA-68, a selective NPSR antagonist (at a single dose of 40 mg/kg), SHA-68 alone and corresponding vehicle (solvent SHA-68) control. To measure anxiety-like behavior and locomotor activity the open field test was performed. All individuals were killed under anaesthesia and the whole brain was excised. Total mRNA was isolated from homogenized samples of the amygdala, hippocampus, hypothalamus, thalamus, cerebellum, and brainstem. Real-time PCR was used for estimation of related NPS, NPSR, neuromedin U (NMU), NMU receptor 2 (NMUR2) and nesfatin-1 precursor nucleobindin-2 (NUCB2) gene expression. RESULTS: Acute escitalopram administration affects the local expression of the examined neuropeptides mRNA in a varied manner depending on brain location. An increase in NPSR and NUCB2 mRNA expression in the hypothalamus and brainstem was abolished by SHA-68 coadministration, while NMU mRNA expression was upregulated after NPSR blockade in the hippocampus and cerebellum. CONCLUSIONS: The pharmacological effects of escitalopram may be connected with local NPSR-related alterations in NPS/NMU/NMUR2 and nesfatin-1 gene expression at the level of selected rat brain regions. A novel alternative mode of SSRI action can be therefore cautiously proposed.
Authors: Ville Pulkkinen; Ritva Haataja; Ulf Hannelius; Otto Helve; Olli M Pitkänen; Riitta Karikoski; Marko Rehn; Riitta Marttila; Cecilia M Lindgren; Johanna Hästbacka; Sture Andersson; Juha Kere; Mikko Hallman; Tarja Laitinen Journal: Ann Med Date: 2006 Impact factor: 4.709
Authors: Stewart D Clark; Dee M Duangdao; Stefan Schulz; Li Zhang; Xiaobin Liu; Yan-Ling Xu; Rainer K Reinscheid Journal: J Comp Neurol Date: 2011-07-01 Impact factor: 3.215
Authors: Yan-Ling Xu; Rainer K Reinscheid; Salvador Huitron-Resendiz; Stewart D Clark; Zhiwei Wang; Steven H Lin; Fernando A Brucher; Joanne Zeng; Nga K Ly; Steven J Henriksen; Luis de Lecea; Olivier Civelli Journal: Neuron Date: 2004-08-19 Impact factor: 17.173
Authors: Tomas Hökfelt; Swapnali Barde; Zhi-Qing David Xu; Eugenia Kuteeva; Joelle Rüegg; Erwan Le Maitre; Mårten Risling; Jan Kehr; Robert Ihnatko; Elvar Theodorsson; Miklos Palkovits; William Deakin; Gyorgy Bagdy; Gabriella Juhasz; H Josée Prud'homme; Naguib Mechawar; Rochellys Diaz-Heijtz; Sven Ove Ögren Journal: Front Neural Circuits Date: 2018-12-21 Impact factor: 3.492